Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Clin Mol Hepatol. 2016;22(3):382-389.   Published online 2016 Sep 25     DOI: https://doi.org/10.3350/cmh.2016.0047
Citations to this article as recorded by Crossref logo
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HB eAg‐negative chronic hepatitis B
Hariklia Kranidioti, Spilios Manolakopoulos, George Kontos, Michael S. Breen, Anastasia Kourikou, Melanie Deutsch, Maria Ester Quesada‐Del‐Bosque, Rocio T. Martinez‐Nunez, Mohammed M. Naiyer, Christopher H. Woelk, Tilman Sanchez‐Elsner, Emilia Hadziyannis
Journal of Viral Hepatitis.2019; 26(6): 697.     CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B
Florian van Bömmel, Thomas Berg
Liver International.2018; 38: 90.     CrossRef
An expert consensus for the management of chronic hepatitis B in Asian Americans
M. J. Tong, C. Q. Pan, S.-H. B. Han, D. S.-K. Lu, S. Raman, K.-Q. Hu, J. K. Lim, H. W. Hann, A. D. Min
Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181.     CrossRef